Mark Cai

Mark joined Sectoral in 2022, and his coverage focuses on China healthcare within the Emerging Market Healthcare Strategy.

Mark graduated in 2016 from Monash University with a Ph.D. in Physiology. He also obtained a B.Sc. Honours in Biochemistry and Pharmacology from Monash University in 2008.

Prior to joining Sectoral, Mark was an in-house healthcare and biotechnology consultant with CMH Healthcare Fund based in Hong Kong, responsible for scientific due diligence and deal execution of private equity investments. He previously worked as a senior research officer in the field of cardiovascular and renal physiology at Monash Biomedicine Discovery Institute, Australia.